RFK Jr. and other Trump officials embrace psychedelics after FDA setback

Cognitive tests suggest psilocybin impairs thinking—but the tests may not tell the full story

New research published in the journal Psychopharmacology shows that psilocybin—the psychedelic compound found in certain “magic” mushrooms—slows reaction time and impairs executive functioning during its acute effects. The study, a systematic review and meta-analysis of 13 experiments, found that people under the influence of psilocybin responded more slowly to cognitive tasks and, to a lesser extent, made more errors, particularly at higher dos…

RFK Jr., other officials embrace psychedelics

WASHINGTON — For decades, proponents of psychedelic drugs have come to Washington with a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for Americans grappling with depression, trauma and other hard-to-treat conditions.

Veterans cross border for forbidden psychedelic treatment that's changing lives after combat

Governor Abbott signs bill expanding ibogaine research in Texas after veterans and advocates push for investigating the psychedelic's potential to treat PTSD.

U.S. Moves Toward Legal Psychedelic Therapy as RFK Jr. Pushes Fast-Track Path

For decades, proponents of psychedelic drugs have come to Washington with a provocative message: Illegal, mind-altering substances like LSD and ecstasy should be approved for Americans grappling with depression, trauma and other hard-to-treat conditions. A presidential administration finally seems to agree. “This line of therapeutics has tremendous advantage if given in a clinical setting and we are working very hard to make sure that happens wi…

RFK Jr. and other Trump admin officials back psychedelics for mental health relief

For decades, advocates of psychedelic substances have brought a bold message to Washington, D.C., that currently illicit, mind-altering drugs, such as LSD and MDMA, should warrant approval for therapeutic use in treating severe depression, PTSD, and other treatment-resistant conditions.